Do you want to read an article? Please log in or register.
Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria
Asthma
Related content
RECOMMENDED
Asthma
Clinical Determinants of Successful Omalizumab Therapy in Severe Allergic Asthma Patients: 4-Year-Long, Real-Life Observation
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Kucharczyk A, Więsik-Szewczyk E, Poznańska A, Jahnz-Różyk K
doi: 10.2147/JAA.S282203
RECOMMENDED
Asthma
Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Puggioni F, Brussino L, Canonica GW, Blasi F, Paggiaro P, Caminati M, Latorre M, Heffler E, Senna G, Severe Asthma Network in Italy (SANI) group.
doi: 10.2147/JAA.S274245
RECOMMENDED
Asthma
Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Just J, Thonnelier C, Bourgoin-Heck M, Mala L, Molimard M, Humbert M, STELLAIR Investigators.
doi: 10.2147/JAA.S310888
RECOMMENDED
Allergic Respiratory Diseases
Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Allergy Clin Immunol Pract
Bousquet J, Humbert M, Gibson PG, Kostikas K, Jaumont X, Pfister P, Nissen F
doi: 10.1016/j.jaip.2021.01.011
COMMENTED
Duration of the efficacy of omalizumab after treatment discontinuation in 'real life' severe asthma
Thorax.
Vennera MDC, Sabadell C, Picado C; Spanish Omalizumab Registry
doi: 10.1136/thoraxjnl-2017-
Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry
Intern Med J.
Gibson PG, Reddel H, McDonald VM, Marks G, Jenkins C, Gillman A, Upham J, Sutherland M, Rimmer J, Thien F, Katsoulotos GP, Cook M, Yang I, Katelaris C, Bowler S, Langton D, Robinson P, Wright C, Yozghatlian V, Burgess S, Sivakumaran P, Jaffe A, Bowden J, Wark PA, Yan KY, Kritikos V, Peters M, Hew M, Aminazad A, Bint M, Guo M
doi: 10.1111/imj.13166.
RECOMMENDED
Asthma
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Respir Med.
Bagnasco D, Brussino L, Bonavia M, Calzolari E, Caminati M, Caruso C, D'Amato M, De Ferrari L, Di Marco F, Imeri G, Di Bona D, Gilardenghi A, Guida G, Lombardi C, Milanese M, Nicolini A, Riccio AM, Rolla G, Santus P, Senna G, Passalacqua G
doi: 10.1016/j.rmed.2020.106080.
Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety
Respir Med.
Mansur AH, Srivastava S, Mitchell V, Sullivan J, Kasujee I
doi: 10.1016/j.rmed.2017.01.008.
RECOMMENDED
Asthma
Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Kavanagh JE, Hearn AP, Dhariwal J, Gráinne d'Ancona, Douiri A, Roxas C, Fernandes M, Green L, Thomson L, Nanzer AM, Kent BD, Jackson DJ
doi: 10.1016/j.chest.2020.08.2083.